menu
    • menu
    [{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"CYBIN","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Ketamine analogs","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Adelia Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"Adelia Therapeutics \/ CYBIN","highestDevelopmentStatusID":"3","companyTruncated":"Adelia Therapeutics \/ CYBIN"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Psychedelic Derivative Compound","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Enveric","highestDevelopmentStatusID":"3","companyTruncated":"Enveric Biosciences \/ Enveric"},{"orgOrder":0,"company":"Invea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Invea Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Invea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Invea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Pritzker Neuropsychiatric Disorders Research Consortium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Verge Genomics \/ Pritzker Neuropsychiatric Disorders Research Consortium","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Pritzker Neuropsychiatric Disorders Research Consortium"},{"orgOrder":0,"company":"Chemify","sponsor":"Prepaire Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Chemify","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Chemify \/ Prepaire Labs","highestDevelopmentStatusID":"3","companyTruncated":"Chemify \/ Prepaire Labs"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Gilgamesh Pharmaceuticals","amount2":2.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":2.02,"dosageForm":"","sponsorNew":"Gilgamesh Pharmaceuticals \/ Abbvie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Gilgamesh Pharmaceuticals \/ Abbvie Inc"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gilgamesh Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Gilgamesh Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : $2,015.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AbbVie and Gilgamesh Collaborate to Develop Next-Gen Therapies for Psychiatric Disorders

                            Details : Under terms of the license agreement, AbbVie and Gilgamesh have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : $65.0 million

                            May 13, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery Platform

                            Sponsor : AbbVie Inc

                            Deal Size : $2,015.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chemify

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Chemify

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery Platform

                            Sponsor : Prepaire Labs

                            Deal Size : $30.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Chemify Partners with Prepaire Labs for AI-Robotics in Opioid Discovery

                            Details : Chemify will design and discover novel non-addictive Opioids as pain modulators, tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery Platform

                            Sponsor : Prepaire Labs

                            Deal Size : $30.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Verge Genomics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Verge Genomics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery Platform

                            Sponsor : Pritzker Neuropsychiatric Disorders Research Consortium

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia...

                            Details : Under the collaboration, Verge will use CONVERGE®, its all-in-human, AI-powered platform, to identify novel therapeutic targets by using data generated from postmortem brain tissue provided by schizophrenia patients and healthy donors.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery Platform

                            Sponsor : Pritzker Neuropsychiatric Disorders Research Consortium

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Invea Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Invea Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery Platform

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Invea Therapeutics Announces Poster Presentations at Keystone Symposia Gut-Brain Axis and Digestive Disease We...

                            Details : Research demonstrates advantage of using AI and ML to deconvolute bidirectional communication network of physical, cellular, and biochemical connections between central nervous system, enteric nervous system, immune system, and GI tract, known as the Gut...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            March 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery Platform

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Enveric Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Enveric Biosciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psychedelic Derivative Compound

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery Platform

                            Sponsor : Enveric Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

                            Details : Enveric intends to expand into a next-generation neuroscience drug discovery platform of novel psychedelics that addresses the large unmet mental health challenges related to CNS indications such as Cancer Related Distress, PTSD, anxiety, depression and ...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 17, 2021

                            Lead Product(s) : Psychedelic Derivative Compound

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery Platform

                            Sponsor : Enveric Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Adelia Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Adelia Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine analogs

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery Platform

                            Sponsor : CYBIN

                            Deal Size : $15.7 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cybin Signs Definitive Agreement To Acquire Adelia Therapeutics As Part Of Its Commitment To Strategic Growth

                            Details : Adelia’s leadership team brings deep clinical and commercialization experience, including past commercial success in psychedelics through the development of proprietary ketamine analogs as well as strong understanding of the underlying science.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 07, 2020

                            Lead Product(s) : Ketamine analogs

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery Platform

                            Sponsor : CYBIN

                            Deal Size : $15.7 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth